Harbin Gloria Pharmaceuticals Co Ltd
SZSE:002437
Wall Street
Price Targets
Price Targets Summary
Harbin Gloria Pharmaceuticals Co Ltd
According to Wall Street analysts, the average 1-year price target for
Harbin Gloria Pharmaceuticals Co Ltd
is 10.05 CNY
.
Operating Income
Forecast
Operating Income Estimate
Harbin Gloria Pharmaceuticals Co Ltd
For the last 8 years the
compound annual growth rate for
Harbin Gloria Pharmaceuticals Co Ltd's operating income is
-15%.
The projected
CAGR
for the next 8 years is
17%.
Net Income
Forecast
Net Income Estimate
Harbin Gloria Pharmaceuticals Co Ltd
For the last 8 years the
compound annual growth rate for
Harbin Gloria Pharmaceuticals Co Ltd's net income is
-19%.
The projected
CAGR
for the next 8 years is
29%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Harbin Gloria Pharmaceuticals Co Ltd's stock price target?
Price Target
10.05
CNY
According to Wall Street analysts, the average 1-year price target for
Harbin Gloria Pharmaceuticals Co Ltd
is 10.05 CNY
.
What is Harbin Gloria Pharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
1%
For the last 8 years the
compound annual growth rate for
Harbin Gloria Pharmaceuticals Co Ltd's revenue is
0%.
The projected
CAGR
for the next 8 years is
1%.
What is Harbin Gloria Pharmaceuticals Co Ltd's Operating Income forecast?
Projected CAGR
17%
For the last 8 years the
compound annual growth rate for
Harbin Gloria Pharmaceuticals Co Ltd's operating income is
-15%.
The projected
CAGR
for the next 8 years is
17%.
What is Harbin Gloria Pharmaceuticals Co Ltd's Net Income forecast?
Projected CAGR
29%
For the last 8 years the
compound annual growth rate for
Harbin Gloria Pharmaceuticals Co Ltd's net income is
-19%.
The projected
CAGR
for the next 8 years is
29%.
You don't have any saved screeners yet
